GSK plc
camlipixant
chronic cough
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for camlipixant in chronic cough are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“Further pivotal readouts expected in 2026: camlipixant (chronic cough);”